Product

Atazanavir

Aliases

REYATAZ®

Name

ATAZANAVIR

INN Name

ATAZANAVIR

FDA Approved

Yes

5 clinical trials

2 organizations

5 indications

1 document

Indication

Indication

Indication

Indication

Healthy Participants

Indication

Clinical trial

A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC

Status: Terminated, Estimated PCD: 2013-01-22

Clinical trial

A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women

Status: Completed, Estimated PCD: 2015-09-22

Clinical trial

An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone

Status: Withdrawn, Estimated PCD: 2014-08-31

Clinical trial

An Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, 3-Sequence, Crossover Design, Relative Bioavailability Study Comparing the Pharmacokinetics of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations (ATV and COBI Oral Mini-tablets; 300 mg and 150 mg, Respectively) and the Coadministration of the Individual Reference Products (REYATAZ [Atazanavir Oral Powder] and TYBOST [Cobicistat Oral Tablet]; 300 mg and 150 mg, Respectively) in Healthy Adults Under Fed Conditions

Status: Completed, Estimated PCD: 2022-07-05

Clinical trial

Population Pharmacokinetics of Antiretroviral in Children

Status: Completed, Estimated PCD: 2022-06-16

Organization

Zydus Lifesciences Limited

Document

DailyMed Label: ATAZANAVIR

Organization

Zydus Pharmaceuticals USA Inc.